FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to a composition for preventing or treating diseases dependent on sex hormones, or for contraception, containing: a) an ester of sorbitan and an unsaturated fatty acid containing two or more -OH (hydroxyl) groups in a polar head group; b) phospholipid; c) a liquid crystal hardener which does not contain an ionized group, and the hydrophobic moiety of which has a triacyl group containing from 15 to 40 carbon atoms or a carbon ring structure; d) water; and e) a gonadotropin-releasing hormone (GnRH) analogue as a pharmaceutically active substance, also relates to a method for preventing or treating sex hormone-dependent diseases, or for contraception, comprising administering a therapeutically effective amount of a composition to a subject, and also relates to use of the composition for preventing or treating diseases dependent on sex hormones, or for contraception, and to use of the composition in the manufacture of a medicinal agent for preventing or treating diseases dependent on sex hormones, or for contraception.
EFFECT: group of inventions provides a significant reduction in the initial release rate and an improved sustained-release profile of the drug due to the preliminary addition of water to the initial sustained-release lipid preparation (compositions of the present invention), containing GnRH analogues, allowing the liquid injectable formulation to form a liquid crystal gel immediately after administration, and also provides significant safety.
20 cl, 9 dwg, 2 tbl, 28 ex
